Partners hit as Reata ends PhIII BEACON trial with bardoxolone in CKD
This article was originally published in Scrip
Executive Summary
Abbott investors sent the company's stock down for the second day in a row after its partner Reata Pharmaceuticals said on 18 October that the private firm had terminated the Phase III BEACON clinical trial evaluating its antioxidant inflammation modulator (AIM) bardoxolone methyl (RTA 402) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes.
You may also be interested in...
Outlook For Reata's Bardoxolone Improves With Phase II Updates
Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).
IPO Update: Three More Biotechs Squeeze Through The Window
What's the best metaphor for the past two weeks of US biotechnology initial public offerings? That would be a sharp intake of air through the teeth – the sound you make when you see someone do something really painful.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.